Biostent cytochalasin B: Will start in March a Phase I safety trial of four different doses and placebo, in 40 angioplasty patients

NeoRx Corp. (NERX), Seattle Product: Biostent cytochalasin B, which prevents the chronic contriction of smooth muscle in response to injury by blocking re-polymerization of actin in cells Indication:...